WallStSmart

Clene Inc. (CLNN)vsJBS N.V. (JBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JBS N.V. generates 46278180% more annual revenue ($91.17B vs $197,000). JBS leads profitability with a 1.2% profit margin vs 0.0%. JBS earns a higher WallStSmart Score of 39/100 (F).

CLNN

Avoid

34

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -28.19

JBS

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 6.0Value: 6.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLNNSignificantly Overvalued (-62.6%)

Margin of Safety

-62.6%

Fair Value

$2.54

Current Price

$3.57

$1.03 premium

UndervaluedFair: $2.54Overvalued

Intrinsic value data unavailable for JBS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLNN3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
233.3%10/10

Revenue surging 233.3% year-over-year

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Debt/EquityHealth
-0.9010/10

Conservative balance sheet, low leverage

JBS3 strengths · Avg: 8.7/10
Return on EquityProfitability
77.9%10/10

Every $100 of equity generates 78 in profit

P/E RatioValuation
12.5x8/10

Attractively priced relative to earnings

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

CLNN4 concerns · Avg: 2.8/10
Market CapQuality
$45.87M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1738.0%2/10

ROE of -1738.0% — below average capital efficiency

JBS4 concerns · Avg: 2.3/10
Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Operating MarginProfitability
3.1%3/10

Operating margin of 3.1%

EPS GrowthGrowth
-57.2%2/10

Earnings declined 57.2%

Debt/EquityHealth
2.971/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CLNN

The strongest argument for CLNN centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 233.3% demonstrates continued momentum.

Bull Case : JBS

The strongest argument for JBS centers on Return on Equity, P/E Ratio, Price/Book. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : CLNN

The primary concerns for CLNN are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : JBS

The primary concerns for JBS are Profit Margin, Operating Margin, EPS Growth. Debt-to-equity of 2.97 is elevated, increasing financial risk. Thin 1.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLNN profiles as a hypergrowth stock while JBS is a value play — different risk/reward profiles.

CLNN is growing revenue faster at 233.3% — sustainability is the question.

JBS generates stronger free cash flow (240M), providing more financial flexibility.

Monitor PACKAGED FOODS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JBS scores higher overall (39/100 vs 34/100) and 13.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clene Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.

JBS N.V.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

JBS N.V., is a protein and food company globally. The company is headquartered in Amstelveen, Netherlands.

Want to dig deeper into these stocks?